CX compounds identified from pharmacophore modeling inhibited cell migration, lung and colon cancer cell proliferation, and colony formation. Mechanistic studies of CX4152 showed that this compound ...

Lung cancer leads global cancer mortality, and non-small-cell variants make up more than 80% of cases. Immune checkpoint inhibitors have transformed therapy yet help only 27–45% of recipients.

Radiation therapy targets lung cancer at all stages, damaging tumor cell DNA to inhibit growth and division. Palliative radiation focuses on symptom relief in polymetastatic disease, using shorter, ...

NHS England has announced the roll-out of a new liquid biopsy blood test to help lung cancer patients receive targeted treatments faster and reduce the need for biopsies. This world-first rollout ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has accepted and granted ...

Catalin Nicola. "It allows us to diagnose lung cancer in its early stages." Lung cancer is the second most common cancer in both men and women in the U.S. The American Cancer Society says the ...

To Joshua Bauml, vice president, lung cancer area stronghold leader at J&J, the company’s experience in multiple myeloma is a blueprint for its strategy in lung cancer. “Look at what we’ve ...

Reckamp, MD, MS, of Cedars-Sinai Cancer. A planned second interim analysis of Pragmatica-Lung data in April found that it was unlikely the investigational combination would lengthen overall ...

May 29 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Daiichi Sankyo (4568.T), opens new tab have withdrawn their U.S. application for an experimental lung cancer treatment after it ...